Apollomics (APLM) Insider Hsien-Shu Tsai Buys 500 Shares
Hsien-Shu Tsai picked up 500 shares of Apollomics, Inc. on June 15, 2026, joining several other insiders making moves.
Reviewed by automated data checks against the source filing. How we make and check alerts
Hsien-Shu Tsai bought 500 shares of Apollomics, Inc. ($APLM) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $APLM is up 64.8% after 1 week, up 38.6% after 1 month and up 52.4% to date (from the $13.85 close on Jun 15, 2026).
APLM
Apollomics, Inc.
Key Points
- Hsien-Shu Tsai picked up 500 shares of Apollomics, Inc. on June 15, 2026.
- The stock traded at $14.49 on Wednesday, resting well below its 52-week high of $42.12.
- Multiple insiders traded shares on June 15, including Chief Financial Officer Lin Peter Kuan-How parting with 10,000 shares.
Get $APLM trade alerts by text
We text you when insiders, Congress or big funds trade $APLM. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Apollomics, Inc. alert may contain errors. Disclosures
Apollomics Insider Trades Feature Hsien-Shu Tsai
On June 15, 2026, Hsien-Shu Tsai added to the recent wave of insider activity at Apollomics, Inc. (NasdaqCM: APLM) by purchasing 500 shares. The transaction added a fresh block of stock to the insider's holdings on a day filled with multiple trades across the executive team.
Where Apollomics Stock Trades Today
The company's shares changed hands at $14.49 on Wednesday. That price places the stock closer to its 52-week low of $10.01 than its peak of $42.12 achieved over the past year. The shares are also trading below both the 50-day moving average of $21.45 and the 200-day moving average of $18.40.
A Busy Day of Insider Moves
The purchase by Hsien-Shu Tsai was part of a larger cluster of transactions reported on June 15, 2026. Chief Financial Officer Lin Peter Kuan-How parted with 10,000 shares. At the same time, Hong-Jung Chen sold 500 shares, and Yi-An Chu also let go of 500 shares. On the buying side, Chen-Huan Jan picked up 500 shares, matching the size of the acquisition made by Hsien-Shu Tsai. These filings provide a clear window into how individual team members are adjusting their personal accounts.
Inside the Business at Apollomics
Apollomics, Inc. operates as a clinical-stage biopharmaceutical company focused on oncology treatments. The team works on discovery and development efforts targeting specific molecular pathways to inhibit cancer growth. Its product portfolio features candidates like Vebreltinib for solid tumors and various immuno-oncology therapies. Headquartered in Foster City, California, the firm maintains a compact team of 14 employees guiding its clinical pipeline forward.
Looking Ahead for APLM
Investors tracking Apollomics will look toward upcoming financial reports and regulatory updates to gauge progress across its clinical trials. The company carries a market capitalization of $69,696,812.71 and reports a negative forward P/E ratio, reflecting its current status as a pre-profitability drug developer. Future regulatory filings will show whether other members of the leadership team alter their positions as the clinical pipeline advances.
Related Filing Alerts
Source: Hsien-Shu Tsai's Form 4 filing on $APLM (Jun 15, 2026). Find the original filing: APLM Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts